Phase II Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Afatinib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Apr 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 01 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.